Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

AACR 2020

27 - 28 Apr 2020
Virtual Annual Meeting
High mortality among hospital-acquired COVID-19 infection in patients with cance...
Dr Arielle Elkrief - University of Montreal Hospital Research Centre, Montreal, ...
High mortality among hospital-acquired COVID-19 infection in patients with cancer: an observational cohort study ( Dr Arielle Elkrief - University of Montreal Hospital Research Centre, Montreal, Canada )
20 Jul 2020
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL ( Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA )
30 Jun 2020
COM701 as a monotherapy and in combination with nivolumab for various advanced s...
Dr. Ecaterina Dumbrava - MD Anderson Cancer Centre, Houston, USA
COM701 as a monotherapy and in combination with nivolumab for various advanced solid tumours ( Dr. Ecaterina Dumbrava - MD Anderson Cancer Centre, Houston, USA )
27 May 2020
COVID-19: Using oncology drugs and surgery during the coronavirus pandemic
Dr. Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy
COVID-19: Using oncology drugs and surgery during the coronavirus pandemic ( Dr. Paolo Ascierto - Istituto Nazionale Tumori, Milan, Italy )
21 May 2020
TERAVOLT: Thoracic cancers indicate an unexpectedly high mortality rate in patie...
Dr Heather Wakelee - Stanford University Medical Center, Stanford, USA
TERAVOLT: Thoracic cancers indicate an unexpectedly high mortality rate in patients with COVID-19 ( Dr Heather Wakelee - Stanford University Medical Center, Stanford, USA )
21 May 2020
IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imp...
Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA
IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imprime PGG, in second-line mTNBC ( Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA )
19 May 2020
A first-of-its-kind prospective study of a multi-cancer blood test to screen and...
Prof Nickolas Papadopoulos - Johns Hopkins Medicine, Baltimore, USA
A first-of-its-kind prospective study of a multi-cancer blood test to screen and manage 10,000 women with no history of cancer ( Prof Nickolas Papadopoulos - Johns Hopkins Medicine, Baltimore, USA )
13 May 2020
I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER...
Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA
I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer ( Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA )
5 May 2020
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients wit...
Prof Grant McArthur - Peter MacCallum Cancer Center, Melbourne, Australia
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutation-positive advanced melanoma ( Prof Grant McArthur - Peter MacCallum Cancer Center, Melbourne, Australia )
1 May 2020
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated m...
Prof Alain Algazi -University of California San Francisco, San Francisco, USA
Continuous vs intermittent dosing of dabrafenib and trametinib in BRAF mutated melanoma ( Prof Alain Algazi -University of California San Francisco, San Francisco, USA )
30 Apr 2020